Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966793 | 0.82 | KDR (0.51) | KDRENPP3AURKAAURKBTPX2 | |
| SCHEMBL3702571 | 0.80 | KDR (0.54) | KDRENPP3AURKAAURKBTPX2 | |
| SCHEMBL2207096 | 0.79 | MAPT (0.50) | KDRENPP3AURKAMAPTLMNA | |
| SCHEMBL1832652 | 0.77 | KDR (0.55) | KDRENPP3AURKAAURKBTPX2 | |
| SCHEMBL2210774 | 0.76 | AURKA (0.49) | KDRENPP3AURKAAURKBTPX2 | |
| SCHEMBL2209315 | 0.76 | MAPT (0.54) | KDRENPP3MAPTLMNAPOLB | |
| SCHEMBL15663382 | 0.76 | MAPT (0.54) | KDRENPP3MAPTLMNATP53 | |
| SCHEMBL3703048 | 0.76 | KDR (0.50) | KDRENPP3AURKAAURKBTPX2 | |
| SCHEMBL2209159 | 0.76 | KDR (0.50) | KDRENPP3AURKAAURKBTPX2 | |
| SCHEMBL3702833 | 0.76 | KDR (0.50) | KDRENPP3AURKAAURKBTPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069297-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | KDR 644/4885ENPP3 1630/4885AURKA 2/4885 |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | KDR 644/4885ENPP3 1630/4885AURKA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.